Computational pharmaceutical analysis of anti-Alzheimer's Chinese medicine Coptidis Rhizoma alkaloids

被引：16

作者：

Hong, Hong-Jye ^{[2
]}

Chen, Po-Yuan ^{[1
]}

Shih, Tzu-Ching ^{[3
]}

Ou, Che-Yen ^{[1
]}

Jhuo, Mien-De ^{[1
]}

Huang, Yen-Yu ^{[1
]}

Cheng, Ciia-Hsing ^{[1
]}

Wu, Yu-Chi ^{[1
]}

Chung, Jing-Gung ^{[1
]}

机构：

[1] China Med Univ, Dept Biol Sci & Technol, Coll Life Sci, Taichung 404, Taiwan

[2] China Med Univ, Coll Chinese Med, Sch Chinese Med, Taichung 404, Taiwan

[3] China Med Univ, Dept Biomed Imaging & Radiol Sci, Taichung 404, Taiwan

来源：

MOLECULAR MEDICINE REPORTS | 2012年 / 5卷 / 01期

关键词：

Alzhimer's disease; AChE inhibitors; Coptidis rhizoma alkaloids; DISEASE; ACETYLCHOLINESTERASE; PROTEIN; INHIBITORS;

D O I：

10.3892/mmr.2011.630

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Alzheimer's disease (AD) is an age-related neurodegenerative disease, affecting over 20 million people worldwide. Until recently, two major hypotheses were proposed regarding the molecular mechanism of pathogenesis: the cholinergic hypothesis and the amyloid cascade hypothesis. At present, acetylcholinesterase inhibitors are the most effective therapy for AD. Most pharmacological research has focused on the ability of acetylcholinesterase to alleviate cholinergic deficit and improve neurotransmission. Coptidis rhizoma and its isolated alkaloids are reported to possess a variety of activities, including neuroprotective and antioxidant effects. However, as yet no theoretical analysis exists to support this hypothesis. To examine this theory, we applied a computational pharmaceutical analysis to reveal that Chinese medicine Coptidis rhizoma alkaloids have much higher activities than Donepezil (commercial name is A ricept) by docking and scoring.

引用

页码：142 / 147

页数：6

共 18 条

[1] Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Aβ secretion
Asai, Masashi
Iwata, Nobuhisa
Yoshikawa, Ayumu
Aizaki, Yoshimi
Ishiura, Shoichi
Saido, Takaomi C.
Maruyama, Kei
[J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (02) : 498 - 502
[2] Towards Improved Acetylcholinesterase Inhibitors: A Structural and Computational Approach
Barril, X.
Orozco, M.
Luque, F. J.
[J]. MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2001, 1 (03) : 255 - 266
[3] Bouzida D, 1999, Pac Symp Biocomput, P426
[4] On-eye measurement of optical performance of rigid gas permeable contact lenses based on ocular and corneal aberrometry
Dorronsoro, C
Barbero, S
Llorente, L
Marcos, S
[J]. OPTOMETRY AND VISION SCIENCE, 2003, 80 (02) : 115 - 125
[5] βD305A mutant of tryptophan synthase shows strongly perturbed allosteric regulation and substrate specificity
Ferrari, D
Yang, LH
Miles, EW
Dunn, MF
[J]. BIOCHEMISTRY, 2001, 40 (25) : 7421 - 7432
[6] Development of BACE1 inhibitors for Alzheimer's disease
Guo, Tao
Hobbs, Doug W.
[J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (15) : 1811 - 1829
[7] Cholinergic deficiency hypothesis in delirium: A synthesis of current evidence
Hshieh, Tammy T.
Fong, Tamara G.
Marcantonio, Edward R.
Inouye, Sharon K.
[J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2008, 63 (07): : 764 - 772
[8] Huang K.C., 1999, PHARM CHINESE HERBS
[9] Jacobsen J Steven, 2005, NeuroRx, V2, P612
[10] Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease
Jann, MW
[J]. PHARMACOTHERAPY, 2000, 20 (01): : 1 - 12

← 1 2 →